Simone Morando - Publications

Vertebral fractures and muscle function in glucocorticoid-treated individuals with Duchenne muscular dystrophy: a cohort study.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: January 05, 2026

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry.

Journal: Annals of clinical and translational neurology

Published: December 29, 2025

Italian validation of the SMA independence scale-upper limb module.

Journal: European journal of pediatrics

Published: March 03, 2025

Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen.

Journal: European journal of neurology

Published: February 05, 2025

Exploratory Analysis of Gut Microbiota Profile in Duchenne Muscular Dystrophy (DMD) Patients with Intellectual Disability.

Journal: Molecular neurobiology

Published: November 07, 2024

Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded.

Journal: European journal of neurology

Published: July 17, 2024

Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module.

Journal: Neuromuscular disorders : NMD

Published: July 11, 2024

Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA.

Journal: Neuromuscular disorders : NMD

Published: February 21, 2024

Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.

Journal: European journal of neurology

Published: November 06, 2023

Long-term clinical and MRI follow-up in two POMT2-related limb girdle muscular dystrophy (LGMDR14) patients.

Journal: Brain & development

Published: December 24, 2022

The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment.

Journal: Neuropathology and applied neurobiology

Published: March 07, 2022

Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy.

Journal: Annals of clinical and translational neurology

Published: December 30, 2021